Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.
$2.26 +0.07 (3.20%)
As of 05/26/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.